Mitochondrial replacement therapy for advanced maternal age and diminished ovarian reserve: Efficacy, challenges, and Vietnamese landscape

Abstract

Mitochondrial replacement therapy (MRT) has emerged as a disruptive frontier in reproductive medicine to address the challenges of advanced maternal age (AMA) and diminished ovarian reserve (DOR). These conditions are primarily driven by mitochondrial dysfunction, which leads to adenosine triphosphate (ATP) depletion, oxidative damage, and increased embryonic aneuploidy. Heterologous techniques, such as maternal spindle transfer (MST) and pronuclear transfer (PNT), have demonstrated high clinical efficacy, with studies reporting fertilization rates up to 88.4% and significantly improved blastocyst formation in patients with poor prognoses. While these methods show promise, autologous strategies utilizing stem cell derived mitochondria offer an alternative to maintain full genetic relatedness and avoid the ethical complexities of "three-parent" embryos. However, MRT remains an investigational procedure globally due to critical safety concerns, including mitochondrial "reversion" where maternal mitochondrial DNA (mtDNA) regains dominance and potential mitonuclear incompatibility. In Vietnam, where infertility affects approximately 7.7% of couples, there is a rising demand for such interventions despite significant gaps in national data and specific regulatory frameworks. Establishing a strategic roadmap that includes a national AMA/DOR database and modernized legal guidelines is essential to ensure the safe and ethical integration of MRT into Vietnam’s clinical landscape.

Keywords

Mitochondrial replacement therapy / Mitochondrial dysfunction / Mitochondrial donation / Advanced maternal age / Diminished ovarian reserve

Conflict of interest statement

The authors declare that there are no conflict of interest.

Acknowledgements

Not applicable.

Funding

This study received no external funding.

Data availability statement

Not applicable.

Authors’ contributions

Van Thinh Ngo and Thanh Luan Nguyen conceptualized and coordinated the study. All authors performed the literature search, drafted, and critically revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Publisher’ s Note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] Chiang JL, Shukla P, Pagidas K, Ahmed NS, Karri S, Gunn DD, et al. Mitochondria in ovarian aging and reproductive longevity. Ageing Res Rev 2020; 63: 101168.

[2] Kobayashi H, Imanaka S. Mitochondrial DNA damage and its repair mechanisms in aging oocytes. Int J Mol Sci 2024; 25(23): 13144.

[3] Zhang X, Zhang L, Xiang W. The impact of mitochondrial dysfunction on ovarian aging. J Transl Med 2025; 23(1): 211.

[4] Subirá J, Soriano MJ, Del Castillo LM, de Los Santos MJ. Mitochondrial replacement techniques to resolve mitochondrial dysfunction and ooplasmic deficiencies: where are we now? Hum Reprod 2025; 40(4): 585-600.

[5] Wolf DP, Mitalipov N, Mitalipov S. Mitochondrial replacement therapy in reproductive medicine. Trends Mol Med 2015; 21(2): 68-76.

[6] Misyura Y, Aydin B, Dorofeyeva U, Hudkova D, Pylypenko N, Vitushynska M, et al. O-068 Mitochondrial replacement therapy effectively enhances embryo quality and pregnancy outcomes in patients with advanced maternal age and diminished ovarian reserve. Hum Reprod 2025; 40(Suppl 1): deaf097-068.

[7] Truong LQ, Luong TB, Tran TH, Dang NH, Nguyen LH, Nguyen TT, et al. Infertility-related stress, social support, and coping of women experiencing infertility in Vietnam. Health Psychol Rep 2022; 10(2): 129-138.

[8] May-Panloup P, Boucret L, Chao de la Barca JM, Desquiret-Dumas V, Ferré-L'Hotellier V, Morinière C, et al. Ovarian ageing: the role of mitochondria in oocytes and follicles. Hum Reprod Update 2016; 22(6): 725-743.

[9] Dupras-Leduc R, Birko S, Ravitsky V. Mitochondrial/nuclear transfer: a literature review of the ethical, legal and social issues. Can J Bioeth 2018; 1(2): 1-17.

[10] Dougherty MP, Dolitsky S, Chattopadhyay R, Sauer MV. Mitochondrial replacement therapy. Curr Opin Obstet Gynecol 2018; 30(4): 217-222.

[11] Braun E. Mitochondrial replacement techniques for treating infertility. J Med Ethics 2025; 52: 346-354.

[12] Zhang J, Wang CW, Krey L, Liu H, Meng L, Blaszczyk A, et al. In vitro maturation of human preovulatory oocytes reconstructed by germinal vesicle transfer. Fertil Steril 1999; 71(4): 726-731.

[13] Liu H, Wang CW, Grifo JA, Krey LC, Zhang J. Reconstruction of mouse oocytes by germinal vesicle transfer: maturity of host oocyte cytoplasm determines meiosis. Hum Reprod 1999; 14(9): 2357-2361.

[14] Tachibana M, Kuno T, Yaegashi N. Mitochondrial replacement therapy and assisted reproductive technology: A paradigm shift toward treatment of genetic diseases in gametes or in early embryos. Reprod Med Biol 2018; 17(4): 421-433.

[15] Castro RJ. Mitochondrial replacement therapy: the UK and US regulatory landscapes. J Law Biosci 2016; 3(3): 726-735.

[16] Zhang J, Zhuang G, Zeng Y, Grifo J, Acosta C, Shu Y, et al. Pregnancy derived from human zygote pronuclear transfer in a patient who had arrested embryos after IVF. Reprod Biomed Online 2016; 33(4): 529-533.

[17] Yamada M, Sato S, Ooka R, Akashi K, Nakamura A, Miyado K, et al. Mitochondrial replacement by genome transfer in human oocytes: Efficacy, concerns, and legality. Reprod Med Biol 2020; 20(1): 53-61.

[18] Zhang J, Liu H, Luo S, Lu Z, Chávez-Badiola A, Liu Z, et al. Live birth derived from oocyte spindle transfer to prevent mitochondrial disease. Reprod Biomed Online 2017; 34(4): 361-368.

[19] Wang T, Sha H, Ji D, Zhang HL, Chen D, Cao Y, et al. Polar body genome transfer for preventing the transmission of inherited mitochondrial diseases. Cell 2014; 157(7): 1591-1604.

[20] Zhang SP, Lu CF, Gong F, Xie PY, Hu L, Zhang SJ, et al. Polar body transfer restores the developmental potential of oocytes to blastocyst stage in a case of repeated embryo fragmentation. J Assist Reprod Genet 2017; 34(5): 563-571.

[21] Wu K, Zhong C, Chen T, Zhang X, Tao W, Zhang J, et al. Polar bodies are efficient donors for reconstruction of human embryos for potential mitochondrial replacement therapy. Cell Res 2017; 27(8): 1069-1072.

[22] Labarta E, de Los Santos MJ, Escribá MJ, Pellicer A, Herraiz S. Mitochondria as a tool for oocyte rejuvenation. Fertil Steril 2019; 111(2): 219-226.

[23] Belousova V, Ignatko I, Bogomazova I, Sosnova E, Pesegova S, Samusevich A, et al. Causes of and solutions to mitochondrial disorders: A literature review. Int J Mol Sci 2025; 26(14): 6645.

[24] van der Reest J, Nardini Cecchino G, Haigis MC, Kordowitzki P. Mitochondria: Their relevance during oocyte ageing. Ageing Res Rev 2021; 70: 101378.

[25] Kristensen SG, Pors SE, Andersen CY. Improving oocyte quality by transfer of autologous mitochondria from fully grown oocytes. Hum Reprod 2017; 32(4): 725-732.

[26] Morimoto Y, Gamage USK, Yamochi T, Saeki N, Morimoto N, Yamanaka M, et al. Mitochondrial transfer into human oocytes improved embryo quality and clinical outcomes in recurrent pregnancy failure cases. Int J Mol Sci 2023; 24(3): 2738.

[27] Labarta E, de Los Santos MJ, Herraiz S, Escribá MJ, Marzal A, Buigues A, et al. Autologous mitochondrial transfer as a complementary technique to intracytoplasmic sperm injection to improve embryo quality in patients undergoing in vitro fertilization-a randomized pilot study. Fertil Steril 2019; 111(1): 86-96.

[28] Kong LH, Liu Z, Li H, Zhu L, Chen SM, Chen SL, et al. Mitochondria transfer from self-granular cells to improve embryos' quality. Zhonghua Fu Chan Ke Za Zhi 2004; 39(2): 105-107.

[29] Jiang Z, Shi C, Han H, Fu M, Zhu H, Han T, et al. Autologous non- invasively derived stem cells mitochondria transfer shows therapeutic advantages in human embryo quality rescue. Biol Res 2023; 56(1): 60.

[30] American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Fertil Steril 2014; 101(3): 633-634.

[31] Havrljenko J, Kopitovic V, Pjevic AT, Milatovic S, Pavlica T, Andric N, et al. The prediction of IVF outcomes with autologous oocytes and the optimal M II oocyte/embryo number for live birth at advanced maternal age. Medicina (Kaunas) 2023; 59(10): 1799.

[32] Ju W, Zhao Y, Yu Y, Zhao S, Xiang S, Lian F. Mechanisms of mitochondrial dysfunction in ovarian aging and potential interventions. Front Endocrinol (Lausanne) 2024; 15: 1361289.

[33] Rodríguez-Varela C, Herraiz S, Labarta E. Mitochondrial enrichment in infertile patients: A review of different mitochondrial replacement therapies. Ther Adv Reprod Health 2021; 15: 26334941211023544.

[34] Tanaka A, Nagayoshi M, Awata S, Himeno N, Tanaka I, Watanabe S, et al. Metaphase II karyoplast transfer from human in-vitro matured oocytes to enucleated mature oocytes. Reprod Biomed Online 2009; 19(4): 514-520.

[35] Costa-Borges N, Nikitos E, Späth K, Miguel-Escalada I, Ma H, Rink K, et al. First pilot study of maternal spindle transfer for the treatment of repeated in vitro fertilization failures in couples with idiopathic infertility. Fertil Steril 2023; 119(6): 964-973.

[36] Tzeng CR, Hsieh RH, Au HK, Yen YH, Chang SJ, Cheng YF. Mitochondria transfer (MIT) into oocyte from autologous cumulus granulosa cells (cGCs). Fertil Steril 2004; 82: S53.

[37] Oktay K, Baltaci V, Sonmezer M, Turan V, Unsal E, Baltaci A, et al. Oogonial precursor cell-derived autologous mitochondria injection to improve outcomes in women with multiple IVF failures due to low oocyte quality: A clinical translation. Reprod Sci 2015; 22(12): 1612-1717.

[38] Ma H, Van Dyken C, Darby H, Mikhalchenko A, Marti-Gutierrez N, Koski A, et al. Germline transmission of donor, maternal and paternal mtDNA in primates. Hum Reprod 2021; 36(2): 493-505.

[39] Sendra L, García-Mares A, Herrero MJ, Aliño SF. Mitochondrial DNA replacement techniques to prevent human mitochondrial diseases. Int J Mol Sci 2021; 22(2): 551.

[40] Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, et al. Mitochondrial diseases. Nat Rev Dis Primers 2016; 2: 16080.

[41] Ma M, Jiang S, Jin W, Li W, Chen C, Lin K, et al. The press-assisted fusion scheme significantly mitigates the quantity of HVJ-E required in mitochondrial replacement techniques. Reproduction 2024; 167(2): e230238.

[42] Zou W, Huang T, Lyu Q. Recent advances in mitochondrial replacement therapy and its future expectations. Clin Transl Discov 2025; 5(1): e70010.

[43] Dimond R. Social and ethical issues in mitochondrial donation. Br Med Bull 2015; 115(1): 173-182.

[44] Appleby JB. The ethical challenges of the clinical introduction of mitochondrial replacement techniques. Med Health Care Philos 2015; 18(4): 501-514.

[45] Lewis MS. Segmented innovation in the legalization of mitochondrial transfer: Lessons from Australia and the United Kingdom. Hous J Health L & Pol’y 2022; 22: 227.

[46] Phuong LTB, Thuc VN, Quan PT, Anh LH, Vinh DQ, Huyen NTT. Selecting euploid embryo for transfer by preimplantation genetic testing for aneuploidy improved clinical outcomes in patients with advanced maternal age. Biomed Res Ther 2019; 6(12): 3541-3549.

[47] Le H, Nguyen DD, Cao AT, Nguyen HTL, Tham DC, Le TD, et al. Comparative effectiveness of mild or conventional GnRH-antagonist protocols for ovarian stimulation in poor responders (Poseidon Group 4). Front Reprod Health 2020; 2: 606036.

[48] Yen TTN, Hoan NP, Yen NTH, Anh NTQ, Phong PH, Minh NN, et al. Comparative embryological outcomes of vitrified and fresh oocytes in patients with diminished ovarian reserve. Med Arch 2025; 79(5): 346-352.

[49] Hoang TTT, Trinh ST, Nguyen NN, Ho MN, Pham MD, Hoang NT, et al. The Impact of FSHR polymorphisms (rs6165 and rs6166) on ovarian response to stimulation in infertile women with diminished ovarian reserve. Appl Clin Genet 2025; 18: 119-129.

[50] Huong NTL, Thuy TT, Anh PTT, Long HB, Thang LD, Ngoc VT, et al. Effects of 100 IU versus 150 IU hCG supplementation on oocyte and embryo quality in patients aged ≥ 35 years: a propensity score-matched analysis. Int J Med Sci 2025; 22(4): 982-989.

[51] Le MT, Nguyen ND, Dang HNT, Nguyen QHV. Does diminished ovarian reserve impact oxidation-reduction potential in follicular fluid? J Int Med Res 2025; 53(6): 3000605251349926.

[52] Nguyen Thanh HNT. # 314: Comparison of dual-trigger and human chorionic gonadotropin-only trigger among diminished ovarian reserve who underwent intracytoplasmic sperm injection: A retrospective cohort study. FertU Reprod 2023; 5(4): 386.

[53] Li M, Zhu Y, Wei J, Chen L, Chen S, Lai D. The global prevalence of premature ovarian insufficiency: A systematic review and meta-analysis. Climacteric 2023; 26(2): 95-102.

[54] Chin AHB, Villalba A, Alon I, Sun N, Yang J. Ethical challenges in extending mitochondrial replacement therapy (MRT) for overcoming poor egg quality in older women without mitochondrial diseases. J Assist Reprod Genet 2025; 42(12): 4131-4141.